Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study
Open Access
- 5 October 2017
- journal article
- case report
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 10 (3), 876-884
- https://doi.org/10.1159/000480696
Abstract
Background: The clinical presentation of Langerhans cell histiocytosis (LCH) is heterogeneous ranging from single-organ involvement to systemic disease causing substantial morbidity and mortality. We describe an unusual course of severe multisystem LCH with spontaneous remission. Case Presentation: We report on a 45-year-old Caucasian woman with cervical cancer, FIGO stage IVB. Five months after the end of combined radiochemotherapy and brachytherapy, the patient was readmitted because of severe dysuria. Sterile leukocyturia was seen, and cystoscopy revealed only 3 unspecific small mucosal lesions compatible with postradiation cystitis. Incidentally, a computed tomography (CT) scan of the body showed diffuse micronodular and cystic lesions in lungs and hypodense lesions in the liver. Biopsies revealed infiltrations of CD1a and Langerin (CD207)-positive histiocytes in the lung, liver, and bladder. Additionally, positron emission tomography-CT (PET-CT) was compatible with bone involvement. Retrospective analysis revealed that the increase in alkaline phosphatase might have been a surrogate of bone marrow infiltration with osseous activity. Repeated pneumothoraces occurred, and only one course of vinblastine-prednisolone could be applied. Despite ongoing tobacco consumption and without further therapy, PET-CT showed considerable remission 2 months later. However, despite stable remission, documented by serial PET and conventional CT scans, persistent infiltration of the bladder by Langerhans histiocytes could still be demonstrated 17 months later. Unfortunately, cervical cancer recurred and progressed. Conclusion: Multisystem LCH may rapidly occur, may be oligosymptomatic and, even in high-risk cases, remission without specific therapy might occur. Whether alkaline phosphatase might be a surrogate to monitor osseous disease activity has to be further explored.Keywords
This publication has 13 references indexed in Scilit:
- Adult Langerhans Cell Histiocytosis As a Diagnostic PitfallJournal of Clinical Oncology, 2016
- MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosisGenes, Chromosomes and Cancer, 2015
- Pulmonary Langerhans Cell HistiocytosisMedicine, 2014
- High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosisBlood, 2014
- Biological and Therapeutic Implications of the BRAF Pathway in Histiocytic DisordersAsco Educational Book, 2014
- Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical Bacillus Calmette–Guérin therapyPathology - Research and Practice, 2014
- Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-NetOrphanet Journal of Rare Diseases, 2013
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Langerhans cell histiocytosis in adultsReport from the International Registry of the Histiocyte SocietyEuropean Journal of Cancer, 2003
- Langerhans cell histiocytosisCancer, 1999